Mark Stovsky | Biochemistry, Genetics and Molecular Biology | Innovative Research Award

Published on by Best Achievements

Innovative Research Award

Mark Stovsky
Cleveland Diagnostics, Inc.,

Mark Stovsky
Affiliation Cleveland Diagnostics, Inc.
Country United States
Scopus ID 6505757427
Documents 25
Citations 527
h-index 11
Subject Area Biochemistry, Genetics and Molecular Biology
Event Global Best Achievements Awards

The Innovative Research Award recognizes distinguished scholarly achievements and sustained contributions to scientific advancement. Mark Stovsky of Cleveland Diagnostics, Inc. has established a notable research profile through research associated with prostate cancer diagnostics, biomarker development, molecular characterization, and translational medicine. His scholarly record reflects sustained engagement with diagnostic research and the investigation of approaches intended to improve clinical assessment and biomedical decision-making.[1]

Abstract

Mark Stovsky is a physician and biomedical researcher whose scholarly activities focus on prostate cancer diagnostics, biomarker research, and translational medicine. His research has included investigations of prostate-specific antigen and structure-based approaches for improving prostate cancer assessment. This work has contributed to the study of diagnostic technologies designed to provide information beyond conventional biomarker measurements and support clinical evaluation. Through research publications and involvement in diagnostic development, Stovsky’s profile connects clinical medicine with biochemical and molecular research. His supplied bibliometric record of 25 documents, 527 citations, and an h-index of 11 reflects sustained scholarly activity within his research area.

Keywords

Innovative Research Award, Mark Stovsky, Cleveland Diagnostics, prostate cancer, diagnostic biomarkers, prostate-specific antigen, IsoPSA, molecular diagnostics, clinical validation, translational medicine, biomedical research, biochemistry, genetics, molecular biology.

Introduction

Scientific innovation in cancer diagnostics depends on the development of reliable biomarkers and analytical approaches capable of providing clinically meaningful information. Prostate-specific antigen is an established component of prostate cancer assessment, but concentration-based interpretation can present limitations because elevated levels may occur in different prostate conditions. Research into molecular and structural characteristics of prostate-specific antigen has therefore explored alternative approaches for improving diagnostic discrimination.[2]

Research Profile

The research profile of Mark Stovsky reflects engagement with urology, cancer diagnostics, biomarker science, and biomedical innovation. His documented scholarly activities include research concerning prostate-specific antigen and diagnostic approaches intended to improve prostate cancer evaluation. The supplied Scopus record identifies 25 documents, 527 citations, and an h-index of 11 under Author ID 6505757427, providing measurable indicators of scholarly productivity and citation visibility.[1]

Research Contributions

An important component of Stovsky’s documented research concerns the investigation of prostate-specific antigen as a biomarker whose structural characteristics may provide information beyond concentration measurements. Research involving prostate-specific antigen and solvent interaction analysis explored a diagnostic assay concept for prostate cancer using urinary samples, contributing to the development of structure-oriented biomarker research.[2]

Publications

Representative research includes an investigation of prostate-specific antigen and solvent interaction analysis published in Urology, followed by clinical validation research concerning IsoPSA published in The Journal of Urology. Together, these studies illustrate a progression from diagnostic assay concepts toward clinical evaluation of structure-based prostate cancer testing.[2][3]

Research Impact

Research impact can be assessed through scholarly publication, citation activity, and contribution to subsequent scientific investigation. The supplied Scopus metrics of 527 citations and an h-index of 11 indicate measurable scholarly attention to Stovsky’s indexed publications. When considered alongside his research in prostate cancer diagnostics and biomarker development, these indicators provide evidence of sustained academic engagement within biomedical research.[1]

Award Suitability

The Innovative Research Award is intended to recognize research characterized by scholarly contribution, originality, and relevance to scientific advancement. Mark Stovsky’s documented work in prostate cancer diagnostics and biomarker research provides a relevant basis for consideration within this category. His research connects biochemical investigation with clinical applications through the study and evaluation of structure-based diagnostic approaches.[2][3]

Conclusion

Mark Stovsky’s academic profile reflects sustained involvement in biomedical research, particularly in prostate cancer diagnostics, biomarker science, and translational medicine. His documented research on prostate-specific antigen and structure-based diagnostic approaches demonstrates continued investigation of methods intended to provide clinically relevant information for cancer assessment.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Mark Stovsky, Author ID 6505757427. Scopus.
    https://www.scopus.com/pages/authors/6505757427
  2. Stovsky, M., et al. (2023). IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study.
    https://doi.org/10.1016/j.urology.2023.01.037
  3. Stovsky, M., et al. (2022). Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature. The Journal of Urology, p150-155.
    https://doi.org/10.1016/j.urology.2022.05.029

Tzong-Shyuan Lee | Biomedicine | Best Researcher Award

Published on by Best Achievements

Prof. Tzong-Shyuan Lee | Biomedicine | Best Researcher Award 

National Taiwan University | Taiwan

Dr. Tzong-Shyuan Lee, DVM, Ph.D., is a distinguished Professor in the Graduate Institute and Department of Physiology at the College of Medicine, National Taiwan University, Taipei, Taiwan. His extensive research focuses on the pathophysiology of age-related diseases, particularly cardiovascular and neurodegenerative disorders. Dr. Lee’s investigations integrate clinical reagents, nutritional compounds, and traditional herbal medicines through comprehensive in vitro and in vivo approaches to explore therapeutic interventions. His pioneering work has identified several molecular targets and elucidated key mechanistic pathways involved in cardiovascular dysfunction, fatty liver disease, chronic kidney disease, and Alzheimer’s disease. With an impressive scholarly record of 144 publications, 7,843 citations across 6,667 documents, and an h-index of 50, Dr. Lee’s contributions have significantly advanced biomedical research on vascular biology and aging. He has also demonstrated outstanding editorial leadership as Associate Editor for Frontiers in Physiology and Journal of Physiological Investigator, and as Academic Editor for Scientifica (Vascular Medicine Section), Exploration of Endocrine and Metabolic Diseases, and Aging Advances. His expertise is further reflected in his role as an invited reviewer for more than 185 scientific journals. Beyond his research and editorial activities, Dr. Lee has provided exemplary academic leadership as Director of the Department and Graduate Institute of Physiology and as Chairman of the Institutional Animal Care and Use Committee at National Taiwan University. His sustained research excellence, coupled with his leadership and service, underscores his status as a leading figure in cardiovascular and aging-related disease research.

Profile: Scopus | Orcid

Featured Publications 

Lee, T.-S., et al. (2025). Genetic deletion of TRPM8 channels restores microvascular function and mitigates chronic kidney disease progression. Free Radical Biology and Medicine.

Lee, T.-S., et al. (2025). Bromelain enhances nitric oxide bioavailability: Bradykinin's link to TRPV1/Ca²⁺/AMPK/autophagy signaling. Biomedicine and Pharmacotherapy.

Lee, T.-S., et al. (2025). Rac1 signaling mediates the protection of apigenin against hepatic lipid accumulation and insulin resistance. Biomedicine and Pharmacotherapy.

Lee, T.-S., et al. (2025). Bromelain prevents Alzheimer's disease progression by suppressing oxidative stress and upregulating apolipoprotein A1 in 5x familial Alzheimer's disease transgenic mice. Journal of Agriculture and Food Research.

Lee, T.-S., et al. (2025). HMGB1 regulates adipocyte lipolysis via caveolin-1 signaling: Implications for metabolic and cardiovascular diseases. International Journal of Molecular Sciences.

Xiao-qian Chen | pharmacology | Best Researcher Award

Published on by Best Achievements

Prof. Dr. Xiao-qian Chen | pharmacology | Best Researcher Award

Prof. Dr. Xiao-qian Chen, Huazhong University of Science and Technology, China.

Prof. Xiao Qian Chen 🧠 is a leading neurobiology and oncology researcher with over 25 high-impact publications 📚. As a Principal Investigator on 10+ national grants, he has pioneered studies on glioblastoma and neuroglobin. A professor since 2007, he’s received multiple awards 🏅 and holds a patent for neural therapy innovation. His international collaborations 🌍 and mentorship of young scientists 👨‍🔬 make him a driving force in translational brain research.

Profile

Scopus Profile

Orcid Profile

🎓 Early Academic Pursuits

Prof. Dr. Xiao Qian Chen embarked on his academic journey with a Bachelor of Medicine from Shanghai Medical University in 1988. He then pursued a Master’s in Medicine specializing in immunology at Peking Union Medical College and the Chinese Academy of Medical Sciences, graduating in 1997, followed by a Ph.D. in Biology from The Hong Kong University of Science and Technology in 2002. His foundational studies equipped him with a robust interdisciplinary grounding in medicine, immunology, and cutting-edge biological research. 🏛️

💼 Professional Endeavors

Following his Ph.D., Xiao Qian Chen served as an Engineer (1997–1999) at the Laboratory of Molecular Virology, CAS, Beijing. He transitioned to clinical work as a Surgeon (1988–1994) at Xi-Yuan Hospital, blending research with hands-on patient care. His postdoctoral stints included work at Peking University Neuroscience Research Institute (2002–2004) and as a Postdoc/Visiting Scholar (2010–2011) at Emory University’s Pharmacology Department. In academia, he rose from Associate Professor (2004–2007) to Professor from November 2007 at the Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan—where he continues to lead cutting-edge research.

🔬 Contributions and Research Focus On Pharmacology 

Prof. Chen’s research centers on neuroglobin biology, glioblastoma immunology, and neuronal survival under stress. As principal investigator, he has led over ten major projects funded by the National Natural Science Foundation of China, exploring mechanisms of glioma cytotoxicity, astrocyte transformation, and neuroprotection through signaling pathways (e.g., EGFR/PTEN/AKT/PD‑L1). Key themes include neuroglobin’s dual role in oxygen sensing and neuroprotection, and the therapeutic targeting of PD‑L1 and metabolic pathways in brain tumors.

🌍 Impact and Influence

Prof. Chen’s body of work has advanced understanding in both neurobiology and cancer biology. He has identified novel molecular targets such as neuroglobin and PD‑L1, elucidating their roles from neurite outgrowth and hypoxia responses to tumor immunity and chemoradiotherapy resistance. His integrative approach blends molecular experiments, in vivo models, and therapeutic studies, influencing subsequent research in glioblastoma treatment and neuroprotective strategies.

🧠 Research Skills

Prof. Chen’s methodology toolbox is robust and diverse:

  • Cell and molecular biology (protein interactions, gene expression)

  • Animal models (glioblastoma, ischemic stroke, autism, depression)

  • Neurochemistry & signaling assays (EGFR/PTEN/AKT, p38/JNK, autophagy pathways)

  • Immunology techniques (PD‑L1/PD‑1, microglia phenotyping, T‑cell infiltration)

  • Translational therapeutics, especially pharmacological modulation (e.g., Piperlongumine, CD73 inhibitors)

🏅 Awards and Honors

Prof. Chen’s excellence has been recognized through prestigious awards:

  • Second Prize, China Medical Science & Technology Award (2006) — for protective mechanisms in astrocytes during cerebral ischemia.

  • Second Prize, Hubei Science & Technology Progress Award (2019) — for work on Piperlongumamide in cancer treatment.

These accolades affirm the scientific and societal relevance of his discoveries.

🏛️ Legacy and Future Contributions

Prof. Chen’s enduring legacy lies in his cross-disciplinary integration of neuroscience and oncology, particularly in harnessing metabolic and immune modulation for disease intervention. Going forward, his ongoing grants (2022–2025) position him to lead breakthroughs in microglia reprogramming, astrocyte plasticity, and glioblastoma therapeutics. The translational promise of his research holds potential for neuroprotective and immunomodulatory therapies in serious CNS disorders.

Publications Top Notes

  1. 📘 Acta Pharmacologica Sinica (2025)
    Title: CD73 inhibitor AB680 suppresses glioblastoma in mice…
    📅 Year: 2025

  2. 🧠 Theranostics (2025)
    Title: A molecularly distinct cell type in the midbrain regulates intermale aggression…
    📅 Year: 2025

  3. 🧬 Journal of Experimental & Clinical Cancer Research (2023)
    Title: Piperlongumine conquers temozolomide chemoradiotherapy resistance…
    📅 Year: 2023

  4. 🧠 Neuroscience Bulletin (2023)
    Title: Neuroglobin Facilitates Neuronal Oxygenation through Tropic Migration…
    📅 Year: 2023

  5. 🧩 Molecular Neurobiology (2023)
    Title: KMT2E Haploinsufficiency Manifests Autism-Like Behaviors…
    📅 Year: 2023

  6. 🔬 Biochemical and Biophysical Research Communications (2021)
    Title: Rapid tumor recurrence in a novel murine GBM surgical model…
    📅 Year: 2021

  7. 🧪 Clinical and Translational Medicine (2020)
    Title: Mannose synergizes with chemoradiotherapy to cure cancer…
    📅 Year: 2020

  8. 🧠 Frontiers in Oncology (2019)
    Title: The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion…
    📅 Year: 2019

  9. 📡 Nature Communications (2019)
    Title: Locus coeruleus-CA1 projections are involved in chronic-depressive stress…
    📅 Year: 2019

  10. 🧫 Neurochemical Research (2019)
    Title: Selective 14-3-3γ Upregulation Promotes Beclin-1-LC3-Autophagic Influx…
    📅 Year: 2019

  11. 💊 Frontiers in Pharmacology (2019)
    Title: The prognostic and therapeutic value of PD-L1 in glioma
    📅 Year: 2019

  12. 🧬 Biochimica et Biophysica Acta – Molecular Basis of Disease (2018)
    Title: PD-L1 confers glioblastoma multiforme malignancy via Ras binding…
    📅 Year: 2018

  13. 🧠 Cell Death & Disease (2018)
    Title: Neuroglobin boosts axon regeneration during ischemic reperfusion…
    📅 Year: 2018